MSD UK in agreement with the Medicines and Healthcare product Regulatory Agency (MHRA) has announced an extension to the shelf-life of of certain batches of Lagevrio® (molnupiravir) 200 mg hard capsules beyond the labelled expiry date by 6, 12 or 18 months. This extension is based on supportive stability data for Lagevrio® which has been approved by the MHRA.
Patients can continue to use the affected batches safely until their extended use by dates listed below. The expiry date extension does not apply to batches of Lagevrio® not listed in the table below.
Batch number
Labelled Expiry Date
(end of the month)
Extended Use by Date
(end of the month)
U035832, U035834, U035826, U035830, U035829, U035827
December 2022
June 2024
CKFWW, CKFWT, CKFXB, U035259, U035349, U035403, U035575, U035580, U035584, U035723, U036097, U036227, U036303, U036096, U036063
January 2023
July 2024
U038932, U038928, U039514, U038931, U039699, U038933, W003017, W001762, W002196, W002251, W002252, W003006, W003015, W001492, W001742, W001757, W001763, W002191, W002192, W002200, W002201, W002209, W003055, W003012
February 2023
August 2024
U040071, U040082, U040308, U040300, W001764, U040316, W002566, W002577, W002582, W003430, W003111, W003431
March 2023
September 2024
2644400, 2620967, 2620965, 2620959, 2644399, W003434, W005862, W005866, W005869, W005872, W005873, W006344, W006347, W006351, W006360, W006363, W006353, W006354, W006793, W006365, W006369, W006358, W006794, W006945
April 2023
October 2024
2620971, 2620975, 2620973, 2620969, 2620977, 2698245, 2678932, 2698247
May 2023
November 2024
W011781, W012460
August 2023
August 2024
W007695, W008022, W007683, W007684, W007693
October 2023
October 2024
W012394, W012403, W012408, W012538, W012585, W017279, 2698249
November 2023
November 2024
2689837, 2689839, 2689841, 2689845, 2689847, 2689851, 2843352, 2689855
December 2023
December 2024
W031114, W031120, W031127
August 2024
February 2025
W032935, W032936, W032940, W033244, W033245, W033246, W032594, W032598, W032911, W032934
September 2024
March 2025
Affected batches of Lagevrio® will be co-packed with a Dear Patient letter to notify patients of the extended use by dates. There is no need to remove the Patient Letter before passing the medicine to the patient. A hard copy of the Direct Healthcare Professional (DHCP) letter will also be included with pharmacy deliveries. While the extension applies to all affected batches, pharmacies are not expected to print additional Dear Patient Letters for stock already on the shelves.
Pharmacy teams should tell patients and caregivers about the extended use by date of the specified batches of Lagevrio®.
Lagevrio® is subject to additional monitoring identified by the black triangle ▼. Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card Scheme see www.mhra.gov.uk/yellowcard.
Company contact point: If you require further information please contact medicalinformationuk@msd.com or call MSD Medical Information services on 0208 154 8000.
The post Lagevrio® (molnupiravir) 200 mg hard capsules – shelf life extension appeared first on Community Pharmacy England.